Insights
Advancing the Science of Precision Delivery.
Explore scientific perspectives, research and clinical updates, publications, and company news from N1 Life.
Featured
At I-RNA 2026, Skin Becomes the Delivery Question
Dr. Xiaoyu Zang's I-RNA 2026 talk placed skin barriers and cellular release in one delivery discussion.
The archive
Ideas. Evidence. Progress.
Scientific perspectives, research from across the field, and news from N1 Life.
50 articles
- Read the Article
GLP-1 Weight Management Brings New Questions to Skin Care
What a user survey and early skin-care studies reveal about needs during GLP-1 weight management.
- Read the Article
IL-23 Peptides Open a New Question for Topical Delivery
An oral IL-23R program and a preclinical topical peptide study reveal different delivery questions.
- Read the Article
Galderma and ZO: Building a Business Around Skin
A $1.5 billion agreement offers a view of the business model connecting dermatology, aesthetics and daily care.
- Read the Article
Circular RNA Calls for a Different Delivery Material
A circular RNA study links lipid structure to protein expression in cells and mice.
- Read the Article
Topical RNA Needs More Than Penetration
A delivery signal, a cellular effect, and a clinical outcome are three different readouts for topical RNA.
- Read the Article
OliX Files to Expand a Hair-Loss RNA Trial. Results Are Still Ahead.
A trial-expansion filing moves an androgen-receptor siRNA program forward without settling its clinical outcome.
- Read the Article
An Eye Drop Aims for the Retina. Delivery Still Needs Proof.
Foventa's retinal eye-drop program makes tissue delivery part of the molecule-selection question.
- Read the Article
Live Skin Bacteria Move Into a Finished Skincare Routine.
A live-bacteria skincare launch raises concrete questions about strain identity, use and finished-product evidence.
- Read the Article
The Active Is Familiar. The Topical Product Can Still Be New.
Two mature actives, two different formulation decisions—and evidence that belongs to the finished product.
- Read the Article
A Skin-Longevity Prescription Combines Actives With Unequal Evidence.
A prescription skincare launch brings together actives with very different levels of human evidence.
- Read the Article
A Peptide Lip Treatment Has to Work as a Gloss
Peptint turns a lip-care ingredient into a colour product people may reapply, leaving finished-formula performance to be tested.
- Read the Article
A Silk-Based Skin Spray, Cleared as a Device
New Day's FDA record shows how a silk-based formulation can take a device path, with a defined use and evidence boundary.
- Read the Article
Four Weeks With Human Skin Outside the Body
A longer-lived human skin model can extend measurement, but remains an experimental model rather than clinical proof.
- Read the Article
Patch Adhesion Is Part of Delivery Evidence
For generic patches, adhesion is observed throughout wear; a good fit at application is not the full result.
- Read the Article
A Stable Formula Still Needs Skin Data
In-formula quality and in-skin delivery are different readouts. A topical program needs both.
- Read the Article
The Vitamin C Core Stayed. The Finished Serum Changed.
A familiar ingredient ratio can anchor a new formula, but it cannot stand in for testing the updated serum.
- Read the Article
Bemotrizinol Enters the U.S. Sunscreen Monograph. Products Still Need Testing.
A new permitted sunscreen active creates a formulation option, while the finished product still needs its own evidence.
- Read the Article
A Scalp Serum Is Also a Three-Month Use Plan
A leave-on scalp product asks users to keep applying it; its use pattern matters as much as its ingredient list.
- Read the Article
Oral JAK Therapy Expands. Topical Treatment Still Needs Its Own Evidence.
The oral approvals sharpen the questions a topical treatment must answer; they do not settle an oral-versus-topical ranking.
- Read the Article
For a Topical Steroid, Bioequivalence Is Measured in Skin
FDA's updated approach asks whether two topical corticosteroid products produce comparable responses in skin.
- Read the Article
Daily Retinol Use Is a Finished-Formula Question
Daily-use positioning depends on tolerance and stability under a defined product and use schedule.
- Read the Article
A Vehicle Arm Is Not an Empty Baseline
Vehicle groups can improve without an active drug. Study design determines what that improvement means.
- Read the Article
Skin Imaging Can Show Structure. Delivery Needs Its Own Test.
High-resolution images can sharpen a skin-development question, but they are not proof of ingredient delivery.
- Read the Article
Delivery Is Now Written Into the Collaboration
A siRNA agreement and a fragrance encapsulation partnership both name delivery work, with very different technical goals.
- Read the Article
A Facial Microbiome Map Needs More Than an Average
Five participants, multiple facial sites and absolute microbial counts show why sampling location matters.
- Read the Article
A New Cosmetic Ingredient Needs Defined Evidence
China's July 2026 rules connect ingredient development with the evidence required for registration or filing.
- Read the Article
A Ceramide Blend Is a Starting Point, Not a Barrier Result
Five listed ceramide classes make composition worth examining; product performance needs its own evidence.
- Read the Article
A Comparator Changes the Formulation Question
A rosacea trial shows why the comparator arm matters before interpreting formulation results.
- Read the Article
What a 120-Day Scalp Study Can Show
A partner's scalp study offers repeated measures, with a clear limit on causal claims.
- Read the Article
At I-RNA 2026, Skin Becomes the Delivery Question
Dr. Xiaoyu Zang's I-RNA 2026 talk placed skin barriers and cellular release in one delivery discussion.
- Read the Article
PDRN Needs a Delivery Readout
PDRN product claims need defined material, a stable formula and measurements in skin.
- Read the Article
GLP1R Genetics Points Toward Psoriatic Disease
Genetic associations sharpen the psoriasis question, while drug response and route of delivery remain untested.
- Read the Article
Access, clinical data, and research tools are moving in parallel across dermatology
Dermatology activity is advancing across access, clinical evidence, pediatric indications, translational tools, and scalp-care research.
- Read the Article
The next competition in high-value actives is route, delivery, and evidence
Competition around high-value actives is shifting from discovery alone toward delivery, route fit, stability, user experience, and evidence.
- Read the Article
N1 Life and CHAPTER XIV announce a strategic partnership in precision skincare
N1 Life's strategic partnership with CHAPTER XIV marks a China-market collaboration around precision delivery, ingredient potential, formulation, and validation.
- Read the Article
Precision skincare needs delivery, data, and product validation in the same system
N1 Life's ICIC 2026 participation highlighted precision skincare as a chain of data, actives, delivery systems, and product validation.
- Read the Article
Eczema standards and vitiligo data are tightening the dermatology evidence frame
Eczema standards and vitiligo data are moving dermatology decisions toward clearer definitions, treatment sequencing, risk background, and mechanism-level support.
- Read the Article
Data becomes valuable when outside teams can see the next decision
The value of public data depends on whether outside teams can understand what it supports, what it does not support, and what decision comes next.
- Read the Article
Skincare messaging is being asked to lead with evidence structure
Positioning-led skincare claims are losing ground when evidence structure, endpoints, populations, duration, and safety boundaries are unclear.
- Read the Article
Dermatology decisions are moving toward stricter evidence sorting
Dermatology updates are tightening around regulatory stage, pediatric guidance, depth of response, treatment positioning, and long-term safety.
- Read the Article
Putting a peptide into a scalp serum is not the same as building the product
A peptide scalp serum becomes a real product only when delivery, formulation stability, tolerability, and long-term use fit work together.
- Read the Article
Peptide hair growth products are exposing the delivery problem
Peptide scalp care is getting hotter, but real differentiation depends on topical delivery, formulation stability, use experience, and evidence.
- Read the Article
Dermatology updates are sharpening the evidence question
Recent dermatology updates show evidence questions tightening around comparators, endpoints, durability, and safety boundaries.
- Read the Article
Dr. Janice Zang named a 2025 Suzhou Young Scientist
Suzhou's 2025 Young Scientist list names N1 Life founder and CEO Dr. Janice Zang.
- Read the Article
In repair and anti-aging, delivery fit is becoming harder to postpone
Repair and anti-aging teams may need to evaluate delivery fit, not only ingredient choice, when a difficult active has to reach the right skin layer.
- Read the Article
Hyaluronic acid is being evaluated as carrier logic
Hyaluronic acid is being reframed from hydration support into carrier logic for topical delivery and formulation evaluation.
- Read the Article
Delivery is moving to the front of skincare strategy
Delivery systems are becoming part of product strategy, not only downstream formulation support.
- Read the Article
Scalp health is becoming a productization challenge
The KilgourMD signal points to scalp health becoming a productization challenge built around active R&D, formulation, delivery, and clinical validation.
- Read the Article
AI can accelerate discovery. It does not remove the formulation barrier
AI can speed candidate discovery, but formulation fit, topical delivery, product feel, and evidence remain the harder development questions.
- Read the Article
Scalp health is becoming a systems problem
KilgourMD's financing signals a scalp-health market moving toward active pipelines, product formulation, clinical validation, and delivery strategy.
Put science to work
Bring the next delivery question.
Talk with N1 about the active, target tissue, and evidence your program needs.